Free Trial
→ Today's free pick (on me) (From Behind the Markets) (Ad)tc pixel
NASDAQ:CINGW

Cingulate Earnings Date & Estimates

$0.0020 0.00 (-4.88%)
As of 01:44 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cingulate is estimated to report earnings on Wednesday, November 18, 2026, before market opens.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cingulate

Cingulate is expected to post earnings of -$0.4325 per share on revenue of $540 thousand.

Consensus Estimates

Consensus EPS
-$0.4325
Expected Revenue
$540 thousand

Prepare for the Earnings Call

Cingulate Earnings FAQ

Cingulate (NASDAQ:CINGW) is estimated to report earnings on Wednesday, November 18, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Cingulate to post earnings of -$0.4325 per share for the quarter.

The consensus revenue estimate for Cingulate is $540 thousand for the quarter.

Cingulate Earnings Headlines

No headlines for this company have been tracked by MarketBeat.com
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CINGW) is a clinical-stage biopharmaceutical company developing prescription treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. The company’s development programs are based on its proprietary Precision Timed Release (PTR) drug-delivery platform.

Its ADHD candidates include CTx-1301, which uses dexmethylphenidate, and CTx-1302, which uses d-amphetamine. The formulations are designed to release medication in separate phases after a single morning dose, with the goal of providing extended symptom control throughout the day. These candidates are investigational and are not approved for commercial use.

Cingulate is based in the United States and is focused on developing its drug candidates for potential use in the U.S. prescription market.

View Cingulate Profile
Earnings Tools